Nano formulation Approaches for Amphotericin B: A Review of Pharmaceutical and Pharmacological Foundations

Muzammil Husain[1], Sachin Chordiya[2]*

[1]Department of Pharmaceutics, Nagaon Education Society's, Gangamai Institute of Pharmacy Dhule, Maharashtra, India 424005

[2]Department of Pharmaceutical Chemistry, Nagaon Education Society's, Gangamai Institute of Pharmacy Dhule, Maharashtra, India 424005

**** Corresponding Author***

Muzammil Husain

Department of Pharmaceutics, Nagaon Education Societys's
Gangamai Institute of Pharmacy, Dhule, Maharashtra
Orchid ID: 0000-0003-2922-0608

Abstract:

Amphotericin B is recovered as a by-product of the soil actinomycete Streptomyces nodosus fermentation. It was initially isolated at Amphotericin B trial reports of antifungal action. Although Amphotericin B is a well-known antifungal agent, it's been difficult to put it in the essential medicine kit due to its marked side effects, adverse effects, and dose frequency. The therapeutic efficacy of this drug is, however, constrained. The amount administered affects the kidneys' toxicity, neurotoxicity, hepatotoxicity, and certain reactions may occur throughout the infusion. It is imperative to concentrate on treating patients with invasive fungus. To reduce its side effects the first attempt was made in 1980. The creation of innovative, less hazardous lipid-based polyene formulations was introduced, opening up new possibilities for treatment. in the late 1980s and early 1990s, it marked as a critical turning point in antifungal chemotherapy. Over the past 50 years, various fungal infections in the human body have been successfully treated in clinical settings using AmB's distinctive structure. In this review we have explored the pharmaceutical and pharmacological profile of AmB's and discussed its possibilities towards various nano formulations to reduce its dose, enhance bioavailability and improved therapeutic effects, and the novel strategies to overcome its undesired effects.

Keywords: Amphotericin B, antifungal, toxicity, Nano formulation, chemotherapy

1. *INTRODUCTION*

Many researchers are interested in using pharmaceutical nano-formulations for medication delivery applications(1–3). These Nano-formulations are tailored to the intended delivery site and improve the characteristics of conventional medications(4) The fabrication of biomaterials and active implants, as well as the improvement of therapeutics(5), in vivo imaging(6), in vitro diagnostics(7), and the bioavailability of poorly soluble pharmaceuticals can all be enhanced using canonization(8). Nano Drug Delivery Systems (NDDS) is a common name for the use of nanotechnology in drug delivery(9,10). Because of their exceptional qualities and adaptable dimensional structures, carbon nanomaterials have drawn the attention of researchers in the field of therapeutic applications(11,12). Also, due to their electrical characteristics like conductivity and current resistance, many cellular structures are used for numerous biological processes, and a large surface area for effective heat transport (13). Internalization, carbon nanomaterials (CNMs) are well suited for applications such as the movement of genes(14), the presence of compounds that prevent cell toxicity(15), the imaging of biological processes(16), the detection of biological substances(17), and the development of tissues(16). Future uses for several different carbon-based nanomaterials with varying characteristics, such as Science is interested in nanostructures like graphene, carbon nanotubes, fullerenes, Nano diamonds, and quantum dots (18,19). These Nano formulations are reported to have potential in managing various pharmacological conditions using chemical entities such as Amphotericin B.

Amphotericin B is recovered as a by-product of the soil actinomycete Streptomyces nodosus fermentation. It was initially isolated at Amphotericin B trial reports of antifungal action (20), according to historical descriptions by Dutcher, which were published in 1956 (21). Amphotericin B has been extremely important through effective treatment plans; systemic fungal infections are treated. Amphotericin's broad use in many institutions continues to increase despite the development and study of azoles for the treatment of similar infections, producing a large body of evidence on its safety and efficacy. For many illnesses, amphotericin B continues to be the preferred medication(22). The safety and efficacy of this medication as a local therapy for the management of fungal cystitis, peritonitis, dermatomes, and ophthalmic infections, among other conditions, have also been studied in different current biological studies(23). The commercially available preparation of amphotericin B for intravenous injection is sold in 50-mg vials and may also contain trace amounts of amphotericin A and other minor impurities (24). Because it is amphoteric, amphotericin B can produce salts that are capable of dissolving in both basic and acidic media (25). The addition of sodium deoxycholate, which when mixed with amphotericin B creates a colloidal dispersion, is necessary to make it soluble because it is not water soluble. A polyene macrolide is a type of antibiotic that includes amphotericin B(26). Amphotericin B by its chemical structure, polyene antifungal medicines can be recognized. continues to be a viable option for Management strategies for invasive fungal diseases due to Deoxycholate amphotericin B has a potent antifungal action, and its potency is dependent on the concentration utilized. It has been clinically demonstrated to be efficient and efficacious in several animal models (27).

The therapeutic efficacy of this drug is, however, constrained The amount administered affects the kidneys' toxicity, and certain reactions may occur throughout the infusion (28). It is imperative to concentrate on treating patients with invasive aspergillosis and mucormycosis (29). creation of innovative, less hazardous lipid-based polyene formulations were introduced, opening up new possibilities for treatment, in the late 1980s and early 1990s, it marked a critical turning point in antifungal chemotherapy (30). Over the past 50 years, various fungal infections in the human body have been successfully treated in clinical settings using AmB's distinctive structure. The most beneficial pharmacological characteristics that promote continued use of AmB are low fungus protection from broad-spectrum antifungal activity (31). The initial version of AmB, deoxycholate AmB (D AmB), which was created in 1955 to cure systemic fungi infections, had limitations in terms of its detrimental effects on the human body (31). Despite AmB's extensive use, its precise antifungal action mechanism is still unknown (32).

Properties of Amphotericin B

Chemical structure:



Fig. 1 Chemical Structure

Chemical Name:

1*R*,3*S*,5*R*,6*R*,9*R*,11*R*,15*S*,16*R*,17*R*,18*S*,19*E*,21*E*,23*E*,25*E*,27*E*,29*E*,31*E*,33*R*,35*S*,36*R*,37*S*)-33-[(2*R*,3*S*,4*S*,5*S*,6*R*)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid(31).

Molecular Pharmacology of LAmB:

Since they were initially described in medicine delivery in 1965, liposomes have attracted a lot of attention. These little spherical formations have a lipid bilayer surrounding a watery centre(34). The pharmacokinetic characteristics of liposomes are significantly influenced by their particular makeup. It is feasible to lessen the

toxicity of antifungal medications while increasing their efficacy by making liposomes(35).To enable injectable administration, preserve the liposome's capacity to preserve amphotericin B's stability(36), and enable the active component to effectively combat fungus at various tissue locations, a liposome formulation was developed in the case of LAmB. The LAmB unilamellar lipid structure is composed of three main components (37). The primary component of the lipid bilayer is phosphatidylcholine, which is derived from hydrogenated soy. Hydrolysis is prevented at normal body temperature if there is a gel-to-liquid crystal phase transition point over 37 °C (38). The second reason distearoylphosphatidyl glycerol was Its choice was influenced by the fact that its fatty acid chain has a net negative charge and is around the same length as the hydrophobic section of amphotericin B. Amphotericin B forms an ionic link with distearoylphosphatidyl glycerol when liposomes are made in a mildly acidic environment, keeping it confined inside the liposomal bilayer. This interaction between the amino group of amphotericin B and the glycerol results in a net positive charge on the amino group. To bind amphotericin B and keep it within the liposome bilayer, cholesterol is added as the third component. Even if the amphotericin B lipid formulations that are now on the market do not make the drug accessible when taken orally, early attempts to create such a formulation are showing promise Amphocil Amphoteric and Abelcet are two additional lipid amphotericin B formulations that are now being used in clinical settings (39).

Mechanism of Action:

Amphotericin B's antifungal activity can depend on the dosage of the medicine and the organism's sensitivity the drug can have either a deadly or an inhibiting effect on fungus and is affected in vitro by pH, with optimal activity occurring between pH 6.0 and 7.5 (40). It's It binds to ergosterol, a substance found in the membrane of fungus that is susceptible to its actions. is at least partially responsible for its mode of action. The polyenes affect membrane permeability, this binding causes pores to open, ions to be discharged, and ultimately the fungal death. Amphotericin B also exhibits potent cell-mediated immunostimulant effects in mice in addition to its antifungal activity, which includes the potential to increase cell proliferation. However, the amount and time of treatment may affect whether lymphocyte and macrophage activity is activated or depressed. Such consequences' clinical significance is currently unknown (41).



Fig. 2 Drug receptor binding

Also research utilizing fluorescently or gold-labeled liposomes has demonstrated that binding of liposomes to the cell wall of molds and pathogenic yeasts may happen in living animals as well as in vitro testing, irrespective of the presence or absence of amphotericin B. When liposomes without AmB stick to the fungal cell wall, neither the empty liposomes nor the cell wall is harmed. But when liposomes containing amphotericin B bind, fungi are destroyed.



Fig. 3 Cellular Mechanism of Action of Amphotericin B

Absorption:

Amphotericin B is well well-known antifungal agent, but it is observed that it shows a very low absorption rate(42). Recent investigations reveal that it has dual problems of solubility and permeability (43) into the cell wall, as well as being problematic for effective oral and per-oral delivery. To overcome these problems some researchers are continuously investigating novel formulation preparations. Preparation of an ionic-liquid-in-water nanoemulsion drug delivery system that harnesses the unique properties of ionic liquids found effective incase of this case (44).

Distribution:

Amphotericin B is highly distributed in various organs, comprising the liver, spleen, bone marrow, kidneys, and lungs. While comparing amphotericin B lipid complex with liposomal amphotericin B, liposomal amphotericin B shows higher distribution than amphotericin B lipid complex but when administered intrathecally it fails to cross the blood-brain barrier (≤5% of serum levels concentration). Also, it has reported different interindividual variability in pharmacokinetic profiles based on age, gender, and disease. Moreover, recent studies highlight the emerging problem of drug resistance associated with amphotericin B (45). Which was found during the in vitro activity of cryptic species isolates (46). There are certain drawbacks to using amphotericin B systemically for medicinal purposes. Because of harmful effects, an optimal dose cannot be

provided; also, in some organs, insufficient concentrations are attained, particularly in the kidney and CSF(47). Human blood plasma carries major parts of Albumin, globulin, Fibrinogen, and other proteins. Amphotericin B binds to approximately 90% of plasma proteins. which is mainly responsible for its cumulative effects and promotes its toxicity. Additionally, due to lower bioavailability, its therapeutic efficacy remains questionable. A formulation that can enhance its lipophilicity and permeability, as BCS class II drugs could reduce its toxic effect and promote its pharmacological profile.

Metabolism:

The highest bioactivity of AMB is reported in the presence of fetal bovine serum, indicating that AMB metabolism requires all families of CYP450 enzymes. A recent research study shows that steroids majorly influence the process of biotransformation of amphotericin B (AmB) such as ergosterol and other ergostane sterols, which results in disruption of the integrity and key functions of the plasma membrane(48). In Cytosole, AMB is found to enhance resistance due to enhanced ergosterol synthesis and aberrant amino acid and glucose metabolism (49). Moreover, AMB also modulates the ATP synthesis in mitochondria via regulation of the oxidation process. The recent finding supports its involvement, in an in vitro study, AMB showed enhanced expression of genes involved in iron homeostasis and ATP synthesis (50), but its in vivo data is lacking, studies supporting its in vivo ATP synthesis phenomenon may contribute to its therapeutic potential towards cancer and other diseases. Current evidence suggests that Amphotericin B is not metabolized in the liver, However, further srtudy is needed to elucidate its exact metabolism and associated effects.

Elimination:

AMB is preliminarily eliminated via the kidneys. Moreover, the other routes such as the sweat gland, the Mammary gland, and feces. A cohort study of data reveals its cumulative potential over several days based on its renal secretion. As with Conventional Amphotericin B, only 2% to 5% of the dose is excreted in its active form over an extended period. Up to 10% was eliminated unchanged in feces and urine, with the administered dose excreted over 7 days in the case of Liposomal Amphotericin B. Based upon available literature, AMB, due to its cumulative effects, shows nephrotoxicity. Formulations such as SEDDS and SMEDDS can improve their bioavailability and rate of elimination (51).

Bioanalytical issues:

Various methods, including HPLC, LC/MS/MS, or bioassays, can be used to measure the concentration of LAmB (52). It is important to keep in mind that the particular component being tested—whether it be liposome-associated, proprotein-bound, totally amphotericin B, or freely circulating drug—depends on the test being used (53). It follows that caution should be used while analyzing drug concentrations. A crucial stage in the study of LAmB is the extraction of amphotericin B from the liposome. This can be achieved by releasing the active medicinal components by dissolving the liposome in organic solvents such as methanol or DMSO. Then, amphotericin B may be measured by employing assays that can distinguish between the free form and the form attached to liposomes. The amount of amphotericin B in the sample is underestimated due to the liposome was not completely broken down. Analysis of the total amounts of amphotericin B in blood plasma and tissues has significantly advanced our understanding of how LAmB functions in the body. The

quantity of amphotericin B that is biologically active, however, varies widely depending on the sample. Some of these active fractions are incorporated into the liposomes, whereas others could be incorporated into tissues or plasma proteins, or they could be present as unbound drugs. Additionally, it can be challenging to pinpoint the precise sub-compartment where a drug is located when assessing drug concentrations in tissue samples, which makes it challenging to estimate the amount of a physiologically active drug present at the injection site (54).

Preclinical data:

A variety of experimental models have been used by researchers to examine the preclinical pharmacokinetics of LAmB. The pharmacokinetics of LAmB in plasma exhibit a linear pattern, however, its behavior in tissues is more complex, according to research results using mice, rats, and rabbits. Although there are rare occasions where tissue concentrations do not show linearity, in general, tissue concentrations rise in proportion to dosage (55). Even though the plasma showed a greater concentration of LAmB after administration of 7 mg/kg, hepatosplenic absorption decreased to 64% of the whole dosage. The order of highest to lowest concentration of amphotericin B in various tissues was consistently shown to be spleen>liver>kidneys>lungs after LAmB was given to mice in several investigations. Having undergone thorough research, the RES is significant in animal species like rats, rabbits, and dogs, and affects the form of the LAmB concentration-time profile. A contributing reason to the buildup of LAmB in the liver and spleen may be the high macrophage density seen in these tissues. Liposomes, which macrophages can easily phagocytose, may be useful for treating fungi that live inside macrophages, including Cryptococcus neoformans.

The duration LAmB spends in tissues varies and reveals substantial variations amongst tissue beds. In a rat study, the majority of the drug was still detectable 72 hours after administration in the organs of healthy animals. The liver and spleen kept the largest concentrations of LAmB after intravenous treatment, whereas its levels dropped in the kidneys and lungs. Both the brain and spinal cord are accessed by LAmB. The cerebrospinal fluid (CSF) contains moderate levels of amphotericin B, similar to DAmB. However, the cerebrum has a concentration that is almost 100 times higher. The ratio of amphotericin B in the blood plasma to that in the brain tissue at a certain time point was found to be about 3% in a rabbit experiment. An 8-day therapy utilizing LAmB at a dosage of 5 mg per kilogram of body weight per day was administered to a rabbit model., the researchers discovered that 24 hours after the last dose, detectable levels of the medication were found in pulmonary alveolar macrophages, epithelial lining fluid, and the entire homogenized lung tissue. Although it hasn't been precisely measured, LAmB hasn't been able to infiltrate these sub-compartments at the exact depth or rate. Rather than following tissue concentrations over time, the study instead used data taken at a single time point. Approximately 10% of LAmB is thought to permeate each of the lung's subcompartments overall, according to estimates based on the comparison of drug levels in plasma and tissues (56).

Pharmacokinetics in humans:

Similar to lab animals, most of the circulating liposomal amphotericin B (LAmB) in humans is probably made up of intact liposomes. Smaller amounts of the free drug as well as the non-liposomally associated drug are also attached to the Alpha 1-acid glycoprotein (AAG) and human serum albumin (HSA) are two different types of proteins that are present in our blood. Researchers have created population pharmacokinetic models to better understand how LAmB functions in immunocompromised people. The degree of individual variability in terms of drug exposure is also included in these models, along with average values for crucial factors like volume and clearance. The body's total levels of amphotericin B show a drop that can be divided into two or three separate phases. The models have consistently generated estimates for clearance and volume in several patient groups, including those receiving a constant dose of 3 mg/kg/day and those who received an intermittent dose of 10 mg/kg followed by two doses of 5 mg/kg/day. The following list summarises the key conclusions from research on how LAmB is broken down in the human body. When compared to estimates for antifungal medications in the triazole class, the drug's rate of elimination from the body is substantially lower, at around 1-2 liters per hour, and its main concentration site has a capacity of about 20 liters. LAmB's plasma levels must drop to zero before it can be entirely removed from the body, which takes around 152 hours, according to research. The levels of amphotericin B in the bloodstream are higher as compared to amphotericin B deoxycholate when taking into account the larger dosages of LAmB based on weight. The majority of drugs in the body likely do not affect biological functions. Up until it comes into contact with the fungus, the liposome acts as a reservoir or accumulation of medications, delaying the release of the biologically active medicament (57,58).

Pharmacodynamics:

When compared to amphotericin B deoxycholate (DAmB), lamb (LAmB) is less efficient milligram for milligram. This distinction is amply demonstrated in an in vitro model of the human alveolus, where the effective dose (ED50) for LAmB was 1.03 mg/L and for DAmB was 0.12 mg/L. In other animal models of invasive fungal infections, like rabbit aspergillosis and mouse aspergillosis, similar outcomes have been seen. These results show that a considerable percentage of the LAmB's active ingredient is contained within the liposome, rendering it biologically inert. However, LAmB has proven to have antifungal activity in the central nervous system and has successfully stopped fungal growth in the cerebrum in a rabbit model of Candida meningoencephalitis. Additionally, effective in treating CNS aspergillosis in mice, LAmB. The antifungal effect of LAmB has been regularly noted in preclinical trials for disseminated candidiasis, blastomycosis, mucormycosis, histoplasmosis, and cryptococcosis, and it is influenced by the dosage given (59).

Side Effects and Toxicology

To make the original AmB formulations better, numerous initiatives have been made. Finding medicines that are more effective and tolerable is the primary factor driving the development of new AmB products because it is far less hazardous than AmB deoxycholate. The creation of AmB methyl ester was one of the first

innovations. However, further study on this drug was halted due to its substantial neurotoxicity. The majority of attempts to improve AmB over the last three decades have been directed at creating a lipid-conjugated version of the substance. Colloidal dispersion of AmB (ABCD), which consists of disk-shaped structures, AmB lipid complex (Abelcet, formerly ABLC), which is made up of bilayer membranes that resemble ribbons, and AmB liposomal (AB-Lip), which consists of single-layered vesicles containing AmB, are three preparations that have undergone clinical trials and are being considered for commercialization. This new standard for polyene therapy is being established by these lipid-based AmB formulations. They are typically utilized in patients who are unable to take standard AmB because of its potential kidney adverse effects or who already have renal impairment. The occurrence of infusion-related toxicity, which is thought to be brought on by immune cells secreting inflammatory cytokines, places restrictions on the administration of AmB. According to some research, AmB stimulates toll-like receptors, which in turn stimulates immune cells in mammals. More than half of the patients in a study with approximately 400 participants suffered negative side effects while receiving the infusion. The primary toxicity of AmB deoxycholate, which includes symptoms including nausea, vomiting, chills, fever, high or low blood pressure, and low oxygen levels, appears to be lessened by some lipid components. The efficiency of liposomal AmB was compared to conventional AmB as an empirical antifungal treatment for patients with persistent fever and neutropenia in a substantial randomized, double-blind, multicenter trial done by Walsh et al (60). Hyperkalemia, which occurs when potassium is removed from inside cells and may cause deadly ventricular arrhythmias, is the main adverse effect of rapid IV infusion. It has been documented that even when 25 AmB deoxycholate is administered at the prescribed doses and infusion rates, significant cardiac toxicity can still result. Both children and adults with prior heart problems have had bradycardia and ventricular arrhythmias as a result of pharmaceutical overdoses.

Case studies have shown that AmB may have rapid deleterious effects on the heart because arrhythmias have been seen in patients after intravenous injection who had normal levels of potassium and magnesium. The use of AmB has also been linked in some cases with severe hypertension, according to the medical literature. Six out of eight people in the eight documented cases received AmB medication immediately after experiencing a sudden onset of severe hypertension. All of the patients, except one, got an AmB preparation devoid of lipids. The precise mechanism producing severe hypertension is still unknown at this time. The capacity of AmB to create neurotoxins is widely known. Akinetic mutism, diffuse cerebral leukoencephalopathy, hyperthermia, hypotension, confusion, incoherence, delirium, depression, obtundation, psychotic behavior, tremors, convulsions, blurred vision, hearing loss, flaccid quadriparesis, and brachial plexus myelin degeneration are just a few of the neurological symptoms that have been linked to intravenous injection of AmB (61).

Nephrotoxicity

AmB causes kidney damage most likely through many ways (62). There is a noticeable increase in creatinine early in treatment. This is a result of the afferent arteriole's renal vasoconstriction, which is poorly understood.

The deoxycholate moiety may be nephrotoxic, which explains why lipid molecules and AmB deoxycholate have distinct renal toxicity. Additional tube damage results in hypokalemia, hypomagnesemia, and amino acid and bicarbonate loss—conditions that are probably less clinically relevant. Studies on dogs have suggested that increased tubuloglomerular feedback is what causes AmB nephrotoxicity (63). Afferent arteriolar vasoconstriction is mostly brought on by tubuloglomerular feedback, which increases solute transport to the distal tubule. Amphotericin B (AmB) likely causes adenosine to be released locally when it causes vasoconstriction in the afferent arterioles. This release could be a result of AmB's influence on biological membranes, which would boost the availability of monovalent ions to the distal tubule. AmB nephrotoxicity has also been linked to direct vasoconstriction in the renal and systemic circulation, in addition to toxic effects on the afferent arterioles and tubules (64). The infusion of AmB causes a reduction in renal blood flow and a decrease in urine production within minutes even while the systemic blood pressure stays steady. moderate blood flow to the renal medulla, which. This decrease in renal perfusion mainly affects the renal medulla, which has a modest blood flow. The kidneys can be affected by the use of high doses of a medication called AmB deoxycholate, leading to renal failure and the need for hemodialysis. **Pathophysiological Role of Amphotericin B**

A main sterol discovered in the membranes of fungi, ergosterol, is essential for many biological processes, including controlling protein sorting, controlling enzymes that are connected with membranes, and regulating membrane properties, including fluidity and permeability. For the treatment of diseases brought on by the fungus Cryptococcus neoformans, it is a crucial target (65). Only three drugs, fluconazole, flucytosine, and amphotericin B (AmB), are now approved to treat cryptococcosis, and each of them focuses on ergosterol or the mechanisms that lead to it. Although the model yeast Saccharomyces cerevisiae has been extensively used to study the synthesis of ergosterol, little is understood regarding the sterols' structure, especially when fungal infections are present. Intriguingly, even though up to 90% of the cellular sterol content is found in the ER, the majority of the sterols synthesized there are transferred to other cellular compartments, particularly the plasma membrane (PM). Promoting sterol mobility is mostly dependent on lipid transport proteins that are unique to sterol and are not part of the secretory system. The two proteins that S. cerevisiae express are oxysterol-binding proteins (OSH) and lipid transfer proteins attached to membrane contact sites (LAM).The seven cytosolic proteins that make up the OSH family are involved while transferring sterols between the endoplasmic reticulum (ER) and other cellular membranes. They localize at membrane contact sites. Unique StART-like domains found in recently discovered LAM proteins bind sterols and are anchored by transmembrane domains. This family of six proteins, Lam1-Lam6, is discovered in S. cerevisiae. Lam1-4 are concentrated where the ER and plasma membrane converges, while Lam5 and Lam6 are located where the ER interacts with mitochondria or vacuoles. The morphology of mitochondria may be significantly influenced by Lam2, also known as Ysp2, which is thought to be a retrograde sterol transporter that moves sterols from the plasma membrane into the endoplasmic reticulum (66).

Clinical Indications:

Amphotericin B, the first antifungal medication ever created, is authorized for the treatment of several severe fungal illnesses, such as aspergillosis, blastomycosis, mucormycosis, aspergillosis, and sporotrichosis. Deoxycholate, the original form of amphotericin B, is known to have considerable renal toxicity, which may restrict its use or necessitate lower doses, finally resulting in treatment failure. Because they have a decreased risk of toxicity, lipid-based formulations of amphotericin B are favored to address this. Amphotericin B has been granted a license to treat invasive candidiasis and candidemia as a result of several research demonstrating its effectiveness. In resource-constrained environments, lipid-based formulations are advised as second-line therapy in the latest guidelines from the Infectious Diseases Society of America (IDSA), whereas the deoxycholate formulation is regarded as a third-line choice (67). For the same reason, amphotericin B is rarely used; instead, echinocandins and other medications are safer and as effective. It is important to keep in mind that the deoxycholate formulation is still the recommended treatment for individuals with disseminated candidiasis despite its high tolerance. When treating endophthalmitis or Candida meningitis, L-AmB is the medication of choice because of its improved ability to reach the central nervous system. Many serious and sometimes fatal endemic fungal diseases are advised to start with amphotericin B formulations. Amphotericin B is the main medication used to treat cryptococcal meningitis during the induction phase, along with flucytosine. Lipid-based formulations are suggested for people who have had organ transplants. Histoplasmosis, blastomycosis, and coccidioidomycosis can all be treated with amphotericin B. For the treatment of serious infections, it is advised as the first line of treatment (68). As the initial course of treatment for mucormycosis, liposomal amphotericin B is advised. Additionally, L-AmB can be used to treat sporotrichosis, especially in cases when the condition has spread widely or is severe.43 Amphotericin B denotes aspergillosis treatment. However, based on the effectiveness in a multicenter trial, voriconazole is the recommended treatment for aspergillosis (69). Amphotericin B is essential for treating mycoses in pregnant women since the triazole class is forbidden because of its proven teratogenicity (70).

Contraindication

Since the US FDA gave Amphotericin B approval, it has been regarded as the standard therapy for invasive fungal infections (71). However, numerous fungi have evolved resistance to its antifungal properties, including species of Candida, Aspergillus, Rhodotorula, Mucor, and Rhizopus. This drug kills the fungus cells by attaching to the ergosterol in the membrane, making it more permeable. Due to its low absorption through the gastrointestinal tract, mostly because of its hydrophobic nature, it is delivered intravenously (72). Amphotericin B doesn't interact with the CYP450 enzyme system like some other medications do. Sadly, it is frequently accompanied by negative side effects such as nephrotoxicity and infusion-related symptoms like fever, chills, hypotension, appetite loss, nausea, vomiting, headaches, and fast breathing. Amphotericin B continues to be the first line of defense against serious and potentially fatal systemic fungal infections despite these limitations. Newer formulations including liposomal amphotericin B and lipid amphotericin B complexes have been developed to reduce its adverse effects (73).

Nano pharmaceuticals

Nano pharmaceuticals are a new class of drugs and drug delivery systems that use nanotechnology to create materials at the nanoscale (1-100 nm) for various therapeutic and diagnostic applications (74). Due to several issues, including the blood-ocular barrier, the cornea, and the fast evacuation of eye drops through the tear ducts, administering medication to the eyes is difficult. The vitreous, sclera, conjunctiva, and cornea operate as barriers that restrict medication's penetration, making it difficult for it to reach the rear of the eye as a result of these variables by enabling the penetration of therapeutic agents into ocular tissues, the use of Nano medicines has revolutionized the treatment of eye diseases, in particular cataracts and diabetic retinopathy. By using this novel strategy, Nano medicines successfully reduce intraocular pressure, addressing the main contributing factor to blindness. They also improve the therapeutic and drug-release profiles, reducing the side effects that are frequently associated with drugs. Nanotechnology has garnered a lot of attention from the international community; Forbes named it one of the top five emerging technologies to watch over the coming ten years. This increased interest makes it seem appropriate to do a full analysis of the Nanomedicines that are now approved. The future of nanotechnology in medical applications has been thoroughly examined in several studies and review papers. Although the FDA has approved about 100 nanomedicines, detailed information about the most recent market trends in this area is lacking. The primary issues with conventional drug-delivery systems (DDSs) will be discussed in this presentation, which will also highlight recent advancements in nanomedicine agents and market trends. Along with the often employed nanocarriers in medical contexts and the commercially accessible nanomedicines, we will also look at the key benefits and drawbacks of using nanotechnology in pharmaceutical applications. We'll also give some information on the size of the global market for nanopharmaceuticals and briefly go into the market dynamics and difficulties facing the commercialization of nanomedicines.

One of the main problems with conventional drug delivery systems (DDSs) is that they can't get rid of all of the leftover substances, which could leave poisons and non-biodegradable substances in the patient's body (75). The solubility of pharmaceuticals in conventional DDSs is frequently low, and many of these systems demonstrate a significant first burst of drug release right after delivery. In contrast to conventional DDSs, Nanopharmaceuticals have many characteristics that make them a possible answer to these issues. Here is a list of these advantages. Nanoparticles (NPs) are substantially smaller than the primary components of pharmaceuticals made traditionally (76). Small-molecule therapies can be combined with these tiny Nanocarriers to create fully functional Nano medicines. Using nano-formulations of pharmaceutical substances can enhance the transport of drugs to specific tissues with higher accuracy while lowering the necessary dosage and potential adverse side effects. By applying the passive method of directing and gathering very small medications to malignant tumors and other affected sites, the enhanced permeability and retention (EPR) effect can successfully cure a range of medical disorders. Nano-sized formulations offer a greater amount of active ingredients and better absorption into the body compared to traditional micronized formulations. Nanoparticles demonstrate enhanced effectiveness and safety. In contrast to conventional treatments, nano-medicines can be more cost-effective. They can also provide the desired therapeutic effect within a specific timeframe by releasing the drug at a steady rate (77).

Nano crystal

Fig. 4 Microscopic Structure of Nano Crystal

Crystals, nanoparticles, and microparticles can be created by the body on its own utilizing proteins, minerals, or metabolites, or they can go inside the body as particles from the outside world or the workplace. When these particles build up in tissues, they can cause several negative side effects, including swelling, cell death, the development of granulomas, tissue scarring, and obstruction of the excretory organs. It is not entirely known how crystals, nanoparticles, and microparticles cause these impacts in underlying biological systems (78). Nevertheless, a few common mechanisms appear to be at work independently of the unique traits of the particles, such as their size, shape, or composition. On the other hand, some mechanisms might only work in certain particle characteristics. When there is an overabundance of particular ions in body fluids, excretory organs, including the urine and biliary tracts in humans, are vulnerable to crystal formation. Numerous conditions, including arterial calcification and atherosclerosis, might trigger the crystallization process. Furthermore, the buildup of fibrillary proteins, which are proteins that have been incorrectly folded, is linked to disorders like Parkinson's and Alzheimer'sWhat's important to note that is the current study indicates that these fibrils can occasionally unite to form protein crystals, which are more stable and need less energy to generate than fibrils (79).

Polymeric nanoparticles:

In monolithic polymers, which are continuous molecules, solvents can pass through both macro- and mesopores. Today, a large variety of organic and inorganic monomers can be used with many different synthetic processes to create monoliths (80). With these techniques, it is possible to precisely manage the size of the pores without using a lot of pressure, which is a key element in deciding how effectively analytes can be transferred to the solid's interior surface and how smoothly solvents and samples may pass through the monolith. The creation of an emulsion and subsequent polymerization of the outer phase is a common method for controlling the porosity of the final polymer. With the help of this technique, it is possible to produce macroporous monolithic solids and hydrophobic and hydrophilic polymers with interconnected porous networks of organic solvents and two non-aqueous phases that don't typically mix can be combined to form

monoliths (81). In contrast to this type of mixture, the common water/oil system is more stable. In the natural world, monoliths may be made of inorganic components like silica polymers, organic components like acrylate/methacrylate polymers, or a combination of both. These polymers can also have nano- or microparticles that are integrated into their structure or that are connected to their surface, creating solid monolithic materials with embedded solid particles. Combining polymers with nano or microparticles is a typical way to produce sophisticated hybrid polymeric materials. These hybrid polymeric solids are created by synthesizing emulsions with magnetic nanoparticles (MNPs) or carbon nanoparticles (CNPs).

Magnetic nanoparticles;

Magnetic nano- and microparticle-based separations have received a lot of attention over the past twenty years. In the domains of chemistry, biochemistry, biology, and medicine, they produced a wide range of application possibilities (82). Above all, at both the micro and pilot plant scales, they allow for the simple and quick removal of substances and organisms linked to functionalized magnetic particles from intricate heterogeneous reaction mixtures. More specific and selective interactions are those between antigen and antibody or avidin and biotin By observing to the surfaces of magnetic particles of the proper sizes (nano- or micro-), functional groups, such as strong or weak bases or acids, particular dye ligands (like Cibachrom Blue F3GA), or transition metal chelates, these particles can be used for complex analysis, separation, and purification of substances (83).

Dendrimers;

To achieve efficient biopharmaceutical and pharmacological activity in various dosage forms, dendrimers are essential. Through two key processes—formulation and Nano construction—they help in the dispersion of drugs. While noncovalent interactions are used for drug trapping in Nano constructs, dendrimers are covalently attached (84). To illustrate these occurrences, PAMAM dendrimers have been used. The creation of persistent pharmacological complexes with plasmid DNA, oligonucleotides, and antibodies is made possible by their spherical shape, which has defined branching and a large number of terminal groups. Due to the gaps and many terminal groups present in these dendrimers, they can solubilize a wide range of hydrophobic groups from various families. The cationic charge on the surface of these molecules should be taken into consideration as it may affect how the cell membrane functions. Increased sensitivity, an enhanced ability to pass through the skin, and accurate medication targeting are among the benefits of these modifications (85).

AuNPs



Fig. 5 various types of Gold nanoparticles

Metallic nanoparticles known as inorganic nanoparticles have an exterior shell formed of organic molecules and a center made of metal oxide or other inorganic elements. These nanoparticles have been employed in many procedures for the treatment, identification, and immunotherapy of cancer (86). These nanoparticles include MSNs, AgNPs, CNTs, QDs, and AuNPs as examples. Particularly tiny gold particles known as AuNPs have a size range of 1 to 100 nm. AuNPs can have a red or purple appearance depending on their size (87). According to the study, it is now possible to synthesize gold nanoparticles (AuNPs) in an environmentally friendly way. A straightforward, non-physical method was developed by Trouiller et al. to quickly create well-defined spherical AuNPs without the need for further reduction procedures. Among the many advantageous properties of spherical AuNPs are their low toxicity, ease of synthesis, homogeneous size and shape, biocompatibility, superior tissue permeability, and simplicity in surface modification. Wang et al.'s spherical AuNPs have found extensive use. Gemcitabine (Gem), a drug used to treat lung cancer, was successfully loaded into AuNPs. The results demonstrated that these nanospheres' strong biocompatibility, minimal toxicity, and significant therapeutic benefits surpassed those of free medications.

Conclusion:

Amphotericin B is a well-known antifungal agent being practiced in the clinical regimens over several decades, however due to its marked and reported toxicities by the US FDA and other regulatory authorities, its essential to formulate its formulation which can reduce its all undesired effects and minimize the dose as well as to enhance its therapeutic effect and pharmacological efficacy. Attempts were made in the 20th century, but they failed to comply with all desired requirements. Still, this medication is being used due to its specificity towards fungal infections. Nano formulations are the answer to all these questions. Nano formulation strategy in the build of amphotericin B or its salt forms. Nano formulation, such as Nano crystals, dendrimers, carbon nanoparticles, etc., could be an effective pharmaceutical strategy to overcome its undesired effects and reduce its dose frequency. Apart from these, the combination with monoclonal antibodies could also be used for targeted drug delivery. As the pharmacological and therapeutic profile of Amphotericin B suggests, apart from its therapeutic potential towards fungal infections, it has potential towards other infections such as

leishmaniosis. Preparation in the form of AuNP could be a milestone in therapeutics, as it could reduce dose frequency and enhance bioavailability.

Author Contributions: Investigation, writing—original draft preparation, writing—review and editing, conceptualization, methodology – Muzammil Husain.

Funding: Not Applicable

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Nanoparticles and its biomedical applications in health and diseases: special focus on drug delivery | Environmental Science and Pollution Research [Internet]. [cited 2024 Mar 3]. Available from: https://link.springer.com/article/10.1007/s11356-019-05211-0

2. Nanomaterials | Free Full-Text | Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery [Internet]. [cited 2024 Mar 3]. Available from: https://www.mdpi.com/2079-4991/11/1/173

3. Pharmaceutics | Free Full-Text | Development of Pharmaceutical Nanomedicines: From the Bench to the Market [Internet]. [cited 2024 Mar 3]. Available from: https://www.mdpi.com/1999-4923/14/1/106

4. Pharmaceutics | Free Full-Text | Nano-Formulation Based Intravesical Drug Delivery Systems: An Overview of Versatile Approaches to Improve Urinary Bladder Diseases [Internet]. [cited 2024 Mar 3]. Available from: https://www.mdpi.com/1999-4923/14/9/1909

5. Multifunctional Gold Nanoparticles for Improved Diagnostic and Therapeutic Applications: A Review | Discover Nano [Internet]. [cited 2024 Mar 3]. Available from: https://link.springer.com/article/10.1186/s11671-021-03632-w

6. Recent advances in applications of nanoparticles in SERS in vivo imaging - Du - 2021 - WIREs Nanomedicine and Nanobiotechnology - Wiley Online Library [Internet]. [cited 2024 Mar 3]. Available from: https://wires.onlinelibrary.wiley.com/doi/abs/10.1002/wnan.1672

7. IJMS | Free Full-Text | The Basic Properties of Gold Nanoparticles and their Applications in Tumor Diagnosis and Treatment [Internet]. [cited 2024 Mar 3]. Available from: https://www.mdpi.com/1422-0067/21/7/2480

8. Dambalkar–STUDENT MGG, Khan–GUIDE MN, Kohale–PRINCIPAL NB, Deshmukh–STUDENT MAO. Dissolution Enhancement Technique: A Review [Internet]. [cited 2024 Mar 3]. Available from: https://ijhssm.org/issue_dcp/Dissolution%20Enhancement%20Technique%20A%20Review.pdf

9. Bhardwaj AK, P AK, it, Rehalia A, Singh V, Sharma R. A Review on Nanomaterials for Drug Delivery Systems and Application of Carbon based Nanomaterials. ES Mater Manuf. 2023 Feb 26;Volume 21 September 2023(0):824.

10. Bohnen NI, Grothe MJ, Ray NJ, Müller MLTM, Teipel SJ. Recent advances in cholinergic imaging and cognitive decline—Revisiting the cholinergic hypothesis of dementia. Curr Geriatr Rep. 2018 Mar;7(1):1–11. doi:10.1007/s13670-018-0234-4 PubMed PMID: 29503795; PubMed Central PMCID: PMC5831510.

11. Multifunctional Carbon-Based Nanoparticles: Theranostic Applications in Cancer Therapy and Diagnosis | ACS Applied Bio Materials [Internet]. [cited 2024 Mar 3]. Available from: https://pubs.acs.org/doi/abs/10.1021/acsabm.2c01000

12. Agrawal YO, Husain M, Patil KD, Sodgir V, Patil TS, Agnihotri VV, et al. Verapamil hydrochloride loaded solid lipid nanoparticles: Preparation, optimization, characterisation, and assessment of cardioprotective effect in experimental model of myocardial infarcted rats. Biomed Pharmacother. 2022;154:113429.

13. An L, Yu Y, Cai Q, Mateti S, Li LH, Chen YI. Hexagonal boron nitride nanosheets: Preparation, heat transport property and application as thermally conductive fillers. Prog Mater Sci. 2023 Sep 1;138:101154. doi:10.1016/j.pmatsci.2023.101154

14. Peng Z, Liu X, Zhang W, Zeng Z, Liu Z, Zhang C, et al. Advances in the application, toxicity and degradation of carbon nanomaterials in environment: A review. Environ Int. 2020 Jan 1;134:105298. doi:10.1016/j.envint.2019.105298

15. Sei S, Ahadova A, Keskin DB, Bohaumilitzky L, Gebert J, von Knebel Doeberitz M, et al. Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies. Front Oncol [Internet]. 2023 [cited 2024 Mar 3];13. Available from: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1147590

16. Ehtesabi H, Kalji SO, Ahadian MM. Carbon nanomaterials in prodrug-based therapeutics. J Drug Deliv Sci Technol. 2023 Oct 1;88:104930. doi:10.1016/j.jddst.2023.104930

17. Bakhshandeh B, Sorboni SG, Haghighi DM, Ahmadi F, Dehghani Z, Badiei A. New analytical methods using carbon-based nanomaterials for detection of *Salmonella* species as a major food poisoning organism in water and soil resources. Chemosphere. 2022 Jan 1;287:132243. doi:10.1016/j.chemosphere.2021.132243

18. Carbon-based nanomaterials for targeted cancer nanotherapy: recent trends and future prospects: Journal of Drug Targeting: Vol 29, No 7 [Internet]. [cited 2024 Mar 3]. Available from: https://www.tandfonline.com/doi/abs/10.1080/1061186X.2021.1886301

19. Husain MM. QbD-Driven Development and Validation of a Robust RP-HPLC Method for Quantitative Estimating Doxycycline Hyclate in Bulk and Novel Nanostructured Lipid Carrier Formulation [Internet]. [cited 2025 Sep 15]. Available from: https://foundryjournal.net/wp-content/uploads/2025/08/11.FJ25C732.pdf

20. Enhancing the production of amphotericin B by Strepyomyces nodosus in a 50-ton bioreactor based on comparative genomic analysis | 3 Biotech [Internet]. [cited 2024 Mar 3]. Available from: https://link.springer.com/article/10.1007/s13205-021-02844-2

21. Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections. Infect Dis Ther. 2021 Mar;10(1):115–47. doi:10.1007/s40121-020-00382-7

22. Cavassin FB, Magri MMC, Vidal JE, de Moraes Costa Carlesse FA, Falci DR, Baú-Carneiro JL, et al. Effectiveness, Tolerability, and Safety of Different Amphotericin B Formulations in Invasive Fungal Infections: A Multicenter, Retrospective, Observational Study. Clin Ther. 2024 Feb 24. doi:10.1016/j.clinthera.2024.01.011

23. Approach to the patient with abdominal pain, gas, and bloating - Yamada's Textbook of Gastroenterology - Wiley Online Library [Internet]. [cited 2024 Mar 3]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9781119600206.ch34

24. Kumar M, Kumar D, Mahmood S, Singh V, Chopra S, R. Hilles A, et al. Nanotechnology-driven wound healing potential of asiaticoside: a comprehensive review. RSC Pharm. 2024. doi:10.1039/D3PM00024A

25. Sawangchan P, Kirsch LE, Egito EST. Unveiling the Amphotericin B Degradation Pathway and Its Kinetics in Lipid-Based Solutions. J Pharm Sci. 2021 Mar 1;110(3):1248–58. doi:10.1016/j.xphs.2020.11.004

26. Haro-Reyes T, Díaz-Peralta L, Galván-Hernández A, Rodríguez-López A, Rodríguez-Fragoso L, Ortega-Blake I. Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications. Membranes. 2022 Jul;12(7):7. doi:10.3390/membranes12070681

27. Fernández-García R, Muñoz-García JC, Wallace M, Fabian L, González-Burgos E, Gómez-Serranillos MP, et al. Self-assembling, supramolecular chemistry and pharmacology of amphotericin B: Poly-aggregates, oligomers and monomers. J Controlled Release. 2022 Jan 1;341:716–32. doi:10.1016/j.jconrel.2021.12.019

28. The Problem with Amphotericin | Clinical Drug Investigation [Internet]. [cited 2024 Mar 3]. Available from: https://link.springer.com/article/10.1007/s40261-020-00924-4

29. Brunet K, Rammaert B. Mucormycosis treatment: Recommendations, latest advances, and perspectives. J Mycol Médicale. 2020 Sep 1;30(3):101007. doi:10.1016/j.mycmed.2020.101007

30. Opara EC. Controlled Drug Delivery Systems. CRC Press; 2020. 369 p.

31. AMPHOTERICIN B FROM ANTIFUNGAL TO ANTIVIRAL THERAPY: PROMISING MODERN THERAPEUTIC BRANCH – тема научной статьи по фундаментальной медицине читайте бесплатно текст научно-исследовательской работы в электронной библиотеке КиберЛенинка [Internet]. [cited 2024 Mar 3]. Available from: https://cyberleninka.ru/article/n/amphotericin-b-from-antifungal-to-antiviral-therapy-promising-modern-therapeutic-branch

32. Delhom R, Nelson A, Laux V, Haertlein M, Knecht W, Fragneto G, et al. The antifungal mechanism of amphotericin B elucidated in ergosterol and cholesterol-containing membranes using neutron reflectometry. Nanomaterials. 2020;10(12):2439.

33. PubChem. Amphotericin B [Internet]. [cited 2024 Mar 3]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/5280965

34. Jing H, Wang Y, Desai PR, Ramamurthi KS, Das S. Formation and Properties of a Self-Assembled Nanoparticle-Supported Lipid Bilayer Probed through Molecular Dynamics Simulations. Langmuir. 2020 May 26;36(20):5524–33. doi:10.1021/acs.langmuir.0c00593

35. Boudier A, Mammari N, Lamouroux E, Duval RE. Inorganic Nanoparticles: Tools to Emphasize the Janus Face of Amphotericin B. Antibiotics. 2023;12(10):1543.

36. Sharifi N, Alitaneh Z, Asadi S, Vahidinia Z, Aghaei Zarch SM, Esmaeili A, et al. Developing nanosize carrier systems for Amphotericin-B: A review on the biomedical application of nanoparticles for the treatment of leishmaniasis and fungal infections. Biotechnol J. 2024 Jan;19(1):2300462. doi:10.1002/biot.202300462

37. McKnight CJ, Briggs MS, Gierasch LM. Functional and Nonfunctional LamB Signal Sequences Can Be Distinguished by Their Biophysical Properties. J Biol Chem. 1989 Oct 15;264(29):17293–7. doi:10.1016/S0021-9258(18)71491-9 PubMed PMID: 2677003.

38. Chen J, Cheng ,Dong, Li ,Jun, Wang ,Yong, Guo ,Jian-xin, Chen ,Zhi-peng, et al. Influence of lipid composition on the phase transition temperature of liposomes composed of both DPPC and HSPC. Drug Dev Ind Pharm. 2013 Feb 1;39(2):197–204. doi:10.3109/03639045.2012.668912 PubMed PMID: 22443684.

39. Faustino C, Pinheiro L. Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. Pharmaceutics. 2020 Jan;12(1):1. doi:10.3390/pharmaceutics12010029

40. Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections. Infect Dis Ther. 2021 Mar 1;10(1):115–47. doi:10.1007/s40121-020-00382-7

41. Stone NR, Bicanic T, Salim R, Hope W. Liposomal Amphotericin B (AmBisome®): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016 Mar;76(4):485–500. doi:10.1007/s40265-016-0538-7 PubMed PMID: 26818726; PubMed Central PMCID: PMC4856207.

42. Wasan E, Mandava T, Crespo-Moran P, Nagy A, Wasan KM. Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections. Pharmaceutics. 2022 Oct 28;14(11):2316.

doi:10.3390/pharmaceutics14112316 PubMed PMID: 36365135; PubMed Central PMCID: PMC9697626.

43. Ghadi R, Dand N. BCS class IV drugs: Highly notorious candidates for formulation development. J Control Release Off J Control Release Soc. 2017 Feb 28;248:71–95. doi:10.1016/j.jconrel.2017.01.014 PubMed PMID: 28088572.

44. Esson MM, Mecozzi S. Preparation, Characterization, and Formulation Optimization of Ionic-Liquid-in-Water Nanoemulsions toward Systemic Delivery of Amphotericin B. Mol Pharm. 2020 Jun 1;17(6):2221–6. doi:10.1021/acs.molpharmaceut.9b00809 PubMed PMID: 32343901.

45. Yang YL, Ho YA, Cheng HH, Lo HJ, TSARY Hospitals. Distribution and susceptibility to amphotericin B and fluconazole of Candida spp. isolated from Taiwan. Epidemiol Infect. 2005 Apr;133(2):325–30. doi:10.1017/s0950268804003310 PubMed PMID: 15816158; PubMed Central PMCID: PMC2870252.

46. Escribano P, Gómez A, Reigadas E, Muñoz P, Guinea J, ASPEIN Study Group. In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and/or amphotericin B. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022 Sep;28(9):1291.e7-1291.e10. doi:10.1016/j.cmi.2022.05.013 PubMed PMID: 35597509.

47. Hof H, Kretschmar M. [Rational use of antimycotics against yeast infections]. Immun Infekt. 1995 Dec;23(6):209–15. PubMed PMID: 8582736.

48. Tulloch LB, Tinti M, Wall RJ, Weidt SK, Corpas-Lopez V, Dey G, et al. Sterol 14-alpha demethylase (CYP51) activity in Leishmania donovani is likely dependent upon cytochrome P450 reductase 1. PLoS Pathog. 2024 Jul;20(7):e1012382. doi:10.1371/journal.ppat.1012382 PubMed PMID: 38991025; PubMed Central PMCID: PMC11265716.

49. Zhang L, Xiao J, Du M, Lei W, Yang W, Xue X. Post-translational modifications confer amphotericin B resistance in Candida krusei isolated from a neutropenic patient. Front Immunol. 2023;14:1148681. doi:10.3389/fimmu.2023.1148681 PubMed PMID: 36936926; PubMed Central PMCID: PMC10015421.

50. Pang CNI, Lai YW, Campbell LT, Chen SCA, Carter DA, Wilkins MR. Transcriptome and network analyses in Saccharomyces cerevisiae reveal that amphotericin B and lactoferrin synergy disrupt metal homeostasis and stress response. Sci Rep. 2017 Jan 12;7:40232. doi:10.1038/srep40232 PubMed PMID: 28079179; PubMed Central PMCID: PMC5228129.

51. Gupta S, Kesarla R, Omri A. Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-Emulsifying Systems. Int Sch Res Not. 2013 Jan;2013(1):848043. doi:10.1155/2013/848043

52. Husain M, Agrawal YO. Quality by Design Approach for the Development and Validation of a Robust RP-HPLC Method for the Estimation of Aloe-emodin. Curr Pharm Anal. 2024 Dec;20(7):500–13. doi:10.2174/0115734129330671240812063919

53. Alencar ÉN, Sawangchan P, Kirsch LE, Egito EST. Unveiling the Amphotericin B Degradation Pathway and Its Kinetics in Lipid-Based Solutions. J Pharm Sci. 2021 Mar;110(3):1248–58. doi:10.1016/j.xphs.2020.11.004 PubMed PMID: 33181186.

54. Husain M, Agrawal YO. Quality by Design Approach for the Development and Validation of a Robust RP-HPLC Method for the Estimation of Aloe-emodin. Curr Pharm Anal. 20(7):500–13. doi:10.2174/0115734129330671240812063919

55. Hamill RJ. Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity. Drugs. 2013 Jun 1;73(9):919–34. doi:10.1007/s40265-013-0069-4

56. Echevarría I, Barturen C, Renedo MJ, Dios-Viéitez MC. High-performance liquid chromatographic determination of amphotericin B in plasma and tissue: Application to pharmacokinetic and tissue distribution studies in rats. J Chromatogr A. 1998 Sep 11;819(1):171–6. doi:10.1016/S0021-9673(98)00425-7

57. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009;69(3):361–92. doi:10.2165/00003495-200969030-00010 PubMed PMID: 19275278.

58. Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015 Nov 1;70(11):3116–23. doi:10.1093/jac/dkv236

59. Petraitis V, Petraitiene R, Katragkou A, Maung BBW, Moradi PW, Sussman-Straus GE, et al. Antifungal efficacy of isavuconazole and liposomal amphotericin B in a rabbit model of Exserohilum rostratum meningoencephalitis: A preclinical paradigm for management of CNS phaeohyphomycosis. Med Mycol. 2021 Feb 4;59(2):189–96. doi:10.1093/mmy/myaa102

60. R. Serrano D, P. Ballesteros M, G. Schätzlein A, J. Torrado J, F. Uchegbu I. Amphotericin B Formulations – The Possibility of Generic Competition. Pharm Nanotechnol. 2013 Nov 1;1(4):250–8.

61. Arrais Rodrigues C, Yamamoto ,Mihoko, de Moraes Arantes ,Adriano, Chauffaille ,Maria de Lourdes L. F., Lopes Colombo ,Arnaldo, and Orlando Bordin J. Amphotericin B-Induced Severe Hypertension in a Young Patient: Case Report and Review of the Literature. Ren Fail. 2006 Jan 1;28(2):185–7. doi:10.1080/08860220500531252 PubMed PMID: 16538979.

62. Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renov Dis. 2014 Dec 12;7:457–68. doi:10.2147/IJNRD.S39747 PubMed PMID: 25540591; PubMed Central PMCID: PMC4270362.

63. Paliwal A, Gahtori R, Kumari A, Pandey P. Chapter 6 - Drug resistance and repurposing of existing drugs in Leishmaniasis. In: Samant M, Chandra Pandey S, editors. Pathogenesis, Treatment and Prevention of Leishmaniasis [Internet]. Academic Press; 2021 [cited 2025 Apr 19]. p. 103–24. Available from: https://www.sciencedirect.com/science/article/pii/B9780128228005000135 doi:10.1016/B978-0-12-822800-5.00013-5

64. Perazella MA, Shirali AC. 35 - Kidney Disease Caused by Therapeutic Agents. In: Gilbert SJ, Weiner DE, editors. National Kidney Foundation' s Primer on Kidney Diseases (Seventh Edition) [Internet]. Philadelphia: Elsevier; 2018 [cited 2025 Apr 19]. p. 334–44. Available from: https://www.sciencedirect.com/science/article/pii/B9780323477949000354 doi:10.1016/B978-0-323-47794-9.00035-4

65. Choy HL, Gaylord EA, Doering TL. Ergosterol distribution controls surface structure formation and fungal pathogenicity. mBio. 14(4):e01353-23. doi:10.1128/mbio.01353-23 PubMed PMID: 37409809; PubMed Central PMCID: PMC10470819.

66. Al-Nakeeb Z, Petraitis V, Goodwin J, Petraitiene R, Walsh TJ, Hope WW. Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus. Antimicrob Agents Chemother. 2015 Apr 10;59(5):2735–45. doi:10.1128/aac.04723-14

67. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):e202–64. doi:10.1093/cid/ciw670

68. Rodrigues CF, Henriques M. Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp. Pathogens. 2017 Dec;6(4):4. doi:10.3390/pathogens6040062

69. Cadranel J, Philippe B, Hennequin C, Bergeron A, Bergot E, Bourdin A, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3231–9. doi:10.1007/s10096-012-1690-y PubMed PMID: 22782438; PubMed Central PMCID: PMC3479377.

70. Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections. Infect Dis Ther. 2021 Mar;10(1):115–47. doi:10.1007/s40121-020-00382-7 PubMed PMID: 33523419; PubMed Central PMCID: PMC7954977.

71. Wang X, Mohammad IS, Fan L, Zhao Z, Nurunnabi M, Sallam MA, et al. Delivery strategies of amphotericin B for invasive fungal infections. Acta Pharm Sin B. 2021 Aug 1;Hot Topic Reviews in Drug Delivery11(8):2585–604. doi:10.1016/j.apsb.2021.04.010

72. Azman M, Sabri AH, Anjani QK, Mustaffa MF, Hamid KA. Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery. Pharmaceuticals. 2022 Aug 8;15(8):975. doi:10.3390/ph15080975 PubMed PMID: 36015123; PubMed Central PMCID: PMC9412385.

73. Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis Off J Transplant Soc. 1999 Dec;1(4):273–83. doi:10.1034/j.1399-3062.1999.010406.x PubMed PMID: 11428998.

74. (PDF) Nanopharmaceuticals: Nanopharmaceuticals. ResearchGate. 2024 Oct 22. doi:10.1515/EJNM.2010.3.1.34

75. Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021 Sep 29;26(19):5905. doi:10.3390/molecules26195905 PubMed PMID: 34641447; PubMed Central PMCID: PMC8512302.

76. Husain M, Agrawal Y. Development and Optimization of Doxycycline Hyclate and Aloe-Emodin NLC's Loaded Gel for Diabetic Wound Healing. J Clust Sci. 2025 Jun 2;36(4):128. doi:10.1007/s10876-025-02839-6

77. Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021 Sep 29;26(19):5905. doi:10.3390/molecules26195905 PubMed PMID: 34641447; PubMed Central PMCID: PMC8512302.

78. Tabasum S, Younas M, Zaeem MA, Majeed I, Majeed M, Noreen A, et al. A review on blending of corn starch with natural and synthetic polymers, and inorganic nanoparticles with mathematical modeling. Int J Biol Macromol. 2019 Feb 1;122:969–96. doi:10.1016/j.ijbiomac.2018.10.092

79. Phuna ZX, Panda BP, Shivashekaregowda NKH, Madhavan P. Recent development in nanocrystal based drug delivery for neurodegenerative diseases: Scope, challenges, current and future prospects. J Drug Deliv Sci Technol. 2022 Feb 1;68:102921. doi:10.1016/j.jddst.2021.102921

80. Ding X, Yang J, Dong Y. Advancements in the preparation of high-performance liquid chromatographic organic polymer monoliths for the separation of small-molecule drugs. J Pharm Anal. 2018 Apr 1;8(2):75–85. doi:10.1016/j.jpha.2018.02.001

81. Pladis P, Kiparissides C. Polymerization Reactors. In: Reference Module in Chemistry, Molecular Sciences and Chemical Engineering [Internet]. Elsevier; 2014 [cited 2025 Apr 19]. Available from: https://www.sciencedirect.com/science/article/pii/B9780124095472109084 doi:10.1016/B978-0-12-409547-2.10908-4

82. Rarokar N, Yadav S, Saoji S, Bramhe P, Agade R, Gurav S, et al. Magnetic nanosystem a tool for targeted delivery and diagnostic application: Current challenges and recent advancement. Int J Pharm X. 2024 Jun 1;7:100231. doi:10.1016/j.ijpx.2024.100231

83. Grieshaber D, MacKenzie R, Vörös J, Reimhult E. Electrochemical Biosensors - Sensor Principles and Architectures. Sensors. 2008 Mar;8(3):3. doi:10.3390/s80314000

84. Abedi-Gaballu F, Dehghan G, Ghaffari M, Yekta R, Abbaspour-Ravasjani S, Baradaran B, et al. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today. 2018 Sep;12:177–90. doi:10.1016/j.apmt.2018.05.002 PubMed PMID: 30511014; PubMed Central PMCID: PMC6269116.

85. Yu YQ, Yang X, Wu XF, Fan YB. Enhancing Permeation of Drug Molecules Across the Skin via Delivery in Nanocarriers: Novel Strategies for Effective Transdermal Applications. Front Bioeng Biotechnol. 2021 Mar 29;9:646554. doi:10.3389/fbioe.2021.646554 PubMed PMID: 33855015; PubMed Central PMCID: PMC8039394.

86. Badwaik HR, Kumari L, Nakhate K, Verma VS, Sakure K. Chapter 13 - Phytoconstituent plumbagin: Chemical, biotechnological and pharmaceutical aspects. In: Atta-ur-Rahman, editor. Studies in Natural Products Chemistry [Internet]. Elsevier; 2019 [cited 2025 Apr 19]. p. 415–60. (Bioactive Natural Products). Available from: https://www.sciencedirect.com/science/article/pii/B9780128179017000137 doi:10.1016/B978-0-12-817901-7.00013-7

87. Niżnik Ł, Noga M, Kobylarz D, Frydrych A, Krośniak A, Kapka-Skrzypczak L, et al. Gold Nanoparticles (AuNPs)—Toxicity, Safety and Green Synthesis: A Critical Review. Int J Mol Sci. 2024 Apr 5;25(7):4057. doi:10.3390/ijms25074057 PubMed PMID: 38612865; PubMed Central PMCID: PMC11012566.